Statement on the new master cell "STAP cells".

Professor Shinya Yamanaka of Kyoto University was placed on the (HP) website of university Center for iPS Cell Research , a statement iPS cells ( induced pluripotent stem cells) new master cell for " STAP cells" .
Describes the three points such as " overcoming the risk of cancer " on the current state of iPS cells , it was noted that " the correct information is not shared necessarily " and among researchers and citizens in it.
According to the statement of Professor Yamanaka has been posted on the HP 12 date this month , iPS cells for regenerative medicine is greatly reduced the risk of cancerous compared to iPS cells first announced in 2006 , safety in animal experiments and that they are fully confirmed .
The efficiency of iPS cells can be from normal cells , from 0.1 percent in 2006 , and increased to 20% in 2009 , overseas group " was to iPS cells All cells in 7 days " in the '13 was introduced and also , it was reported in the scientific journals .
The iPS cells have been described that high technology and reproducible hundreds research group has produced in the world , there is a long tradition of research , and it is the driving force that has spread around the world . For STAP cells , while also evaluated as " art of great potential " such as playing a limb or organ , after the future , we have successfully produced in human cells , it was pointed out that the need to verify the reproducibility and safety .
Video message of Professor Yamanaka towards the patient to wait for treatment using iPS cells are also posted on the HP, and called it a " want you to . Relief has reached the practical stage iPS cells" .
Superiority of " STAP cells" It is unwavering feeling when you see the creation process . I would not I feel also seems high reproducibility and safety , but only leave the results in the supplementary exam . I feel that I want you to proceed with his cooperation towards the clinical I will . Please try to access the https://www.cira.kyoto-u.ac.jp/j/index.html If you want to know more information .


京都大の山中伸弥教授は、ｉＰＳ細胞（人工多能性幹細胞）と新しい万能細胞「ＳＴＡＰ細胞」に関する声明を、同大ｉＰＳ細胞研究所のホームページ（ＨＰ）に載せた。
　その中でｉＰＳ細胞の現状について「がん化リスクの克服」など３点を説明し、市民と研究者の間で「必ずしも正しい情報が共有されていない」と指摘した。
　山中教授が今月１２日付でＨＰに掲載した声明によると、再生医療用のｉＰＳ細胞は２００６年に発表した最初のｉＰＳ細胞に比べてがん化のリスクが大幅に減り、安全性は動物実験で十分に確認されているという。
　通常の細胞からｉＰＳ細胞ができる効率は、０６年の０・１％から、０９年には２０％に向上し、１３年には海外グループが「７日間ですべての細胞をｉＰＳ細胞にした」と、科学誌に報告したことも紹介した。
　またｉＰＳ細胞は、世界で何百という研究グループが作製した再現性の高い技術で、長い研究の伝統があることが、世界中に普及した原動力だと説明した。ＳＴＡＰ細胞については、臓器や手足の再生など「大きな可能性のある技術」と評価する一方、将来、人の細胞で作製に成功した後には、安全性や再現性について検証が必要と指摘した。
　ＨＰにはｉＰＳ細胞を使った治療を待つ患者へ向けた山中教授の動画メッセージも掲載され、「ｉＰＳ細胞は実用段階に達した。安心してほしい」と呼びかけた。
作成過程を見たら「ＳＴＡＰ細胞」の優位性は揺るがない感じですね。安全性や再現性も高そうに感じますが追試験に結果をゆだねるしかないでしょうね。臨床に向けて協力体制を組んで進んでほしい気がしますね。詳しい情報を知りたい方はhttps://www.cira.kyoto-u.ac.jp/j/index.htmlにアクセスしてみてください。